Cencora, Inc. $COR Shares Purchased by First Horizon Advisors Inc.

First Horizon Advisors Inc. increased its position in shares of Cencora, Inc. (NYSE:COR) by 1.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,290 shares of the company’s stock after purchasing an additional 147 shares during the quarter. First Horizon Advisors Inc.’s holdings in Cencora were worth $3,086,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Crestwood Advisors Group LLC lifted its stake in Cencora by 18.9% during the 2nd quarter. Crestwood Advisors Group LLC now owns 1,376 shares of the company’s stock valued at $413,000 after acquiring an additional 219 shares during the period. NewSquare Capital LLC lifted its stake in Cencora by 202.6% during the 2nd quarter. NewSquare Capital LLC now owns 233 shares of the company’s stock valued at $70,000 after acquiring an additional 156 shares during the period. Advisors Preferred LLC lifted its position in Cencora by 631.7% during the second quarter. Advisors Preferred LLC now owns 19,120 shares of the company’s stock valued at $5,647,000 after purchasing an additional 16,507 shares during the period. Huntington National Bank lifted its position in Cencora by 3.1% during the second quarter. Huntington National Bank now owns 14,614 shares of the company’s stock valued at $4,382,000 after purchasing an additional 441 shares during the period. Finally, Key Financial Inc acquired a new position in Cencora during the second quarter valued at $428,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on COR shares. Mizuho boosted their target price on shares of Cencora from $334.00 to $340.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. UBS Group boosted their price objective on Cencora from $350.00 to $380.00 and gave the company a “buy” rating in a report on Monday, October 27th. Wells Fargo & Company boosted their price target on Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a report on Wednesday, August 13th. Morgan Stanley set a $330.00 price target on Cencora and gave the company an “equal weight” rating in a report on Wednesday, July 16th. Finally, Evercore ISI set a $340.00 price target on Cencora in a report on Wednesday, October 8th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $329.55.

Cencora Trading Up 2.4%

Shares of COR stock opened at $352.83 on Thursday. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The company has a market cap of $68.41 billion, a price-to-earnings ratio of 36.30, a PEG ratio of 1.56 and a beta of 0.63. The stock has a 50 day simple moving average of $311.49 and a 200-day simple moving average of $298.36. Cencora, Inc. has a 1-year low of $223.92 and a 1-year high of $361.38.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The company had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period in the prior year, the business posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be given a dividend of $0.60 per share. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date is Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is currently 22.63%.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This represents a 11.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 41,544 shares of company stock valued at $12,230,941 in the last three months. Insiders own 10.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.